Farglitazar

Clinical data
Pregnancy category	N/A
ATC code	none
Legal status
Legal status	Development discontinued
Identifiers
IUPAC name N-(o-Benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
CAS Number	196808-45-4 Y
PubChem CID	170364
IUPHAR/BPS	2672
ChemSpider	148961 Y
UNII	3433GY7132
KEGG	D04132
ChEMBL	ChEMBL107367 Y
CompTox Dashboard (EPA)	DTXSID1047310
Chemical and physical data
Formula	C34H30N2O5
Molar mass	546.623 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5
InChI InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 N Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N N
NY (what is this?)  (verify)

Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy.^[1] After reaching phase III for type 2 diabetes, further development was discontinued.^[2][3]